Lentinan could in vivo inhibit the growth of murine sarcoma S-180 cells, human cervical cancer HeLa cells, breast cancer MCF-7 cells, liver cancer HepG2 cells, and squamous cell carcinoma SCC-7 cells in tumor xenograft models, which was attributed to regulation of tumor suppressor p53, caspase and Era genes (89), inhibition of PI3K/Akt/mTOR signaling pathway, and inhibition of angiogenesis (90). This evidence concerns the gene ESR1 and breast carcinoma.